Stay updated on Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.

Latest updates to the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows a 403 Forbidden error, replacing the expected study record content with an access-denied screen. The header and footer remain, but the study details are not accessible.SummaryDifference16%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdds 'Schizophrenia' and 'MedlinePlus Genetics' to the related topics. The revision tag updates from v3.6.5 to v3.6.6, indicating a version change.SummaryDifference0.1%

- Check36 days agoChange DetectedSchizophrenia and MedlinePlus Genetics entries were removed from the MedlinePlus related topics on the page. This shortens the list of contextual topic links presented to users without altering core study information.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page now lists Schizophrenia as the study condition and adds related topics with a MedlinePlus Genetics link. The revision has been updated from v3.6.4 to v3.6.5.SummaryDifference0.1%

- Check50 days agoChange DetectedThe extension study's recruitment is closed, with actual enrollment of 290 participants reported across 94 locations, and the study's start and completion dates have been updated to actual values (start 2022-03-07; primary and study completion 2026-03-25).SummaryDifference12%

- Check57 days agoChange DetectedRevision tag updated to v3.6.4. The glossary-related entries Schizophrenia and related topics: MedlinePlus Genetics, and the older Revision: v3.6.3, were removed.SummaryDifference0.1%

Stay in the know with updates to Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.